Since its first annual report the AKA creative team has been helping Abaxis answer its investor’s questions: Can Abaxis provide a profit center for a physician’s office? Can the traction shown with their VetScan product line be replicated by it’s medical Piccolo line in the $5 billion clinical chemistry market? Can Abaxis substantiate growth and product acceptance through rotor sales? Are physicians and veterinarians “voting with their feet”? (The answer: Yes).